SCHEMBL7523901

SCHEMBL7523901

CN(C(=O)c1ccc(C(=O)O)cc1)c1ccc(C(=O)N(C)c2ccc(/C=C/c3ccccc3)cc2C(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.47
HNF4A P41235 1/20 0.47
APP P05067 1/20 0.46
SRD5A1 P18405 1/20 0.41
SRD5A2 P31213 1/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 1/20 0.41
CASP3 P42574 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1B1 Q16678 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PTPN2 P17706 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7526916 0.90 PTPN1 (0.54) PTPN1HNF4AAPPSRD5A1SRD5A2
SCHEMBL7526903 0.90 PTPN1 (0.54) PTPN1HNF4AAPPSRD5A1SRD5A2
SCHEMBL7650125 0.84 PTPN1 (0.61) PTPN1HNF4AAPPPTPN2PTPN6
SCHEMBL7528663 0.83 SNCA (0.49) PTPN1HNF4AAPPKMT2AHTT
SCHEMBL6677642 0.81 LMNA (0.60) PTPN1HNF4AAPPKMT2ANPC1
SCHEMBL6677639 0.81 LMNA (0.60) PTPN1HNF4AAPPKMT2ANPC1
SCHEMBL7523907 0.80 PTPN1 (0.48) PTPN1HNF4ASRD5A1SRD5A2KMT2A
SCHEMBL7523894 0.80 PTPN1 (0.48) PTPN1HNF4ASRD5A1SRD5A2KMT2A
SCHEMBL7646325 0.78 APP (0.41) PTPN1HNF4AAPPEGFRERBB2
SCHEMBL7531123 0.78 PTPN1 (0.53) PTPN1HNF4AAPPPTPN2PTPN6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US claimed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 PTPN1 1380/4885HNF4A 425/4885APP 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.